SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

Novo Nordisk and Eli Lilly buildings
Editorial
Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work
With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.
November 8, 2024
 · 
4 min read
 · 
Greg Slabodkin
Podcast
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.
November 6, 2024
 · 
1 min read
 · 
Heather McKenzie
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VI
Editorial
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
November 1, 2024
 · 
3 min read
 · 
Greg Slabodkin
Podcast
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; and BioSpace takes a look back at 10 years of NextGen, our annual pick of young biotechs to watch.
October 30, 2024
 · 
1 min read
 · 
Heather McKenzie
Pictured: Pfizer office at its South San Francisco
Earnings
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.
October 29, 2024
 · 
2 min read
 · 
Greg Slabodkin
Artist illustration of stars and stripes colored ballot boxes in U.S. election
Policy
Harris vs. Trump: How Will the Presidential Election Impact Biopharma?
While some analysts say Donald Trump is a wild card when it comes to drug pricing, many argue his presidency would be more positive for the industry overall, as Kamala Harris has her price-cutting sights squarely on Big Pharma.
October 29, 2024
 · 
7 min read
 · 
Greg Slabodkin
Editorial
Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
October 25, 2024
 · 
4 min read
 · 
Greg Slabodkin
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
 · 
1 min read
 · 
Heather McKenzie
Business chart market. Business success strategy. Financial management technology. Internet technology. Business marketing concept.
Editorial
It’s Earnings Season. Here’s What to Watch for Following J&J Beat
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations. Pfizer is projected to have a strong quarter, while Eli Lilly could pull ahead of Novo Nordisk in the obesity space. Moderna, by contrast, has a decidedly negative outlook.
October 18, 2024
 · 
4 min read
 · 
Greg Slabodkin
Podcast
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
October 16, 2024
 · 
1 min read
 · 
Heather McKenzie
3D concept photo of gene editing showing a tweezers inserting a DNA fragment into a larger strand
CRISPR
CRISPR Ex Vivo Gene Editing Gets on Target With Caribou’s Hybrid Guides
While ex vivo genome editing results in highly effective cell therapies, it can lead to off-target effects. Caribou Biosciences has come up with a novel approach for potentially more precise gene editing compared to all-RNA guides.
October 14, 2024
 · 
5 min read
 · 
Greg Slabodkin
Pictured: Entrance to the FTC's office in Washington, DC
Editorial
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
October 11, 2024
 · 
3 min read
 · 
Greg Slabodkin
Matthew Durdy, chief executive of the Cell and Gene Therapy Catapult, speaks at 2024 Meeting on the Mesa at a session also involving (left to right) Pfizer’s Bert Bruce, Bayer Nuno Fontes’, BMS’ Magdalene Pedersen and Eli Lilly’s Manny Simons.
Cell and gene therapy
Big Pharma’s Interest Grows in Evolving Cell and Gene Therapy Sector
Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.
October 9, 2024
 · 
4 min read
 · 
Greg Slabodkin
Podcast
BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
Cell and gene therapy investment rebounds; WuXi Biologics and other companies named in BIOSECURE Act mull options; Bayer, J&J and Pfizer’s recent layoffs; updates from the weight loss space.
October 9, 2024
 · 
1 min read
 · 
Heather McKenzie
Tim Hunt, CEO of the Alliance for Regenerative Medicine, provides welcome remarks at 2024 Cell & Gene Meeting on the Mesa.
Cell and gene therapy
Cell and Gene Therapy Investment Ticks Up After Hard Few Years
Tim Hunt, CEO of the Alliance for Regenerative Medicine, said Monday at the 2024 Cell & Gene Meeting on the Mesa that investments reached $10.9 billion in the first half of this year—outpacing 2019’s $9.8 billion total—but far below the pandemic peak.
October 8, 2024
 · 
4 min read
 · 
Greg Slabodkin
Load More